Biochem/physiol Actions

Target IC₅₀: 7 µM for D-dopachrome tautomerase

Reversible: no

Product does not compete with ATP.

Cell permeable: yes

Primary TargetMIF tautomerize

General description

A cell-permeable isoxazoline compound that displays anti-inflammatory properties. Inhibits MIF tautomerase activity by binding to its catalytic active site (IC₅₀ = 7 µM for D-dopachrome tautomerase) and suppresses the production of TNFα, PGE₂ and COX-2 in human monocytes, and arachidonic acid in RAW 264.7 macrophages. Shown to exhibit antidiabetogenic properties in immunoinflammatory diabetic mouse model. Also available as a 50 mM solution in DMSO (Cat. No. 505225).

A cell-permeable isoxazoline compound that displays anti-inflammatory properties. Inhibits MIF dopachrome tautomerase activity by binding to its catalytic active site (IC₅₀ = 7 µM for D-dopachrome tautomerase) and suppresses the production of TNFα, PGE₂ and COX-2 in human monocytes and arachidonic acid in RAW 264.7 macrophages. Shown to exhibit antidiabetogenic properties in immunoinflammatory diabetic mouse model.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Cvetkovic, I., et al. 2005. Endocrinology, 146, 2942.Lubetsky, J.B., et al. 2002. J. Biol. Chem.277, 24976.

Packaging

Packaged under inert gas

5 mg in Plastic ampoule

Reconstitution

Following reconstituion, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)